par Trapnell, Bruce BC;Inoue, Yoshikazu;Bonella, Francesco;Wang, Tisha;Mc Carthy, Chloé 
;Arai, T.;Akasaka, Keiichi;Mariani, Francesca;Mogulkoc, Nesrin;Song, Jin Woo;Bondue, Benjamin ;Jouneau, Stéphane;Numakura, Tadahisa;Öcal, Nesrin;Mihaltan, Florin;Ataya, Ali;Bendstrup, Elisabeth;Campo, Ilaria;Carey, Brenna;Arena, Ross;Robinson, Baudry;Fleming, Richard;Wasfi, Yasmine;Pratt, Raymond;IMPALA-2 Trial Investigators,
Référence The New England journal of medicine, 393, 8, page (764-773)
Publication Publié, 2025-08-01
;Arai, T.;Akasaka, Keiichi;Mariani, Francesca;Mogulkoc, Nesrin;Song, Jin Woo;Bondue, Benjamin ;Jouneau, Stéphane;Numakura, Tadahisa;Öcal, Nesrin;Mihaltan, Florin;Ataya, Ali;Bendstrup, Elisabeth;Campo, Ilaria;Carey, Brenna;Arena, Ross;Robinson, Baudry;Fleming, Richard;Wasfi, Yasmine;Pratt, Raymond;IMPALA-2 Trial Investigators, Référence The New England journal of medicine, 393, 8, page (764-773)
Publication Publié, 2025-08-01
Article révisé par les pairs
| Résumé : | Autoimmune pulmonary alveolar proteinosis (aPAP) is a rare disease characterized by progressive surfactant accumulation and hypoxemia caused by autoantibodies against granulocyte-macrophage colony-stimulating factor (GM-CSF), which alveolar macrophages require to clear surfactant. Molgramostim is a formulation of inhaled recombinant human GM-CSF, but its efficacy and safety in patients with aPAP have not been studied sufficiently. |
